Moderna shares double on Phase 3 melanoma vaccine success with Merck partner, sparking analyst upgrades and short‑seller losses

MRNA saw its shares more than double on August 19 after a late‑stage trial of its melanoma vaccine, co‑developed with MRK, demonstrated a substantial reduction in tumor recurrence versus Keytruda alone . The Phase 3 readout showed patients lived noticeably longer without their melanoma returning, prompting the market to price in a major commercial upside for the mRNA‑based cancer therapy.

The trial's success reverberated across analyst houses. William Blair upgraded the stock to Outperform on the readout, pointing to regulatory‑filing readiness and revenue diversification; the trial's lead investigator, Prof. Georgina Long of the Melanoma Institute Australia, called the result "a landmark moment". Meanwhile, short‑seller positions were hit hard, with roughly $5 billion of one‑day mark‑to‑market losses, described as a record for the name, as the share price surged. These reactions underscore the market's appetite for breakthrough immunotherapies and the risk of betting against them.

Key details from the study emphasized the synergy of the personalized mRNA vaccine with Merck's checkpoint inhibitor Keytruda, delivering a higher rate of recurrence‑free survival than Keytruda alone. Reuters highlighted the broader outlook, noting that while analysts await full data, the interim results already lifted Moderna's valuation and renewed confidence in its oncology ambitions.

The implications are significant for both companies. Moderna stands to expand its mRNA platform beyond infectious diseases into high‑value oncology markets, potentially reshaping its revenue mix. Merck benefits from a novel companion therapy that could enhance its flagship cancer drug portfolio. Investors will watch for the complete trial data release, regulatory filings, and any subsequent guidance on commercial timelines, which could further influence biotech market dynamics.

Related Stocks

• MRNA
• MRK